Literature DB >> 30446449

The requirement for immune infiltration and organization in the tumor microenvironment for successful immunotherapy in prostate cancer.

Caroline S Jansen1, Nataliya Prokhnevska1, Haydn T Kissick2.   

Abstract

Immunotherapy-particularly immune checkpoint blockade-has seen great success in many tumor types. However, checkpoint-based therapies have not demonstrated high levels of success in prostate cancer, and there is much to be learned from both the successes and failures of these treatments. Here we review the evidence that composition of infiltrating immune cells in the tumor microenvironment is fundamental to the response to immunotherapy. Additionally, we discuss the emerging idea that the organization of these immune cells may also be crucial to this response. In prostate cancer, the composition and organization of the tumor immune microenvironment are preeminent topics of discussion and areas of important future investigation.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  T-cell; cancer; checkpoint blockade; dendritic cell; immune; immunotherapy; macrophage; microenvironment; prostate; stroma; tertiary lymphoid structure; therapeutic vaccination

Mesh:

Year:  2018        PMID: 30446449      PMCID: PMC6513714          DOI: 10.1016/j.urolonc.2018.10.011

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   2.954


  117 in total

Review 1.  Homing and cellular traffic in lymph nodes.

Authors:  Ulrich H von Andrian; Thorsten R Mempel
Journal:  Nat Rev Immunol       Date:  2003-11       Impact factor: 53.106

2.  Lymphoid neogenesis in murine cardiac allografts undergoing chronic rejection.

Authors:  Fady K Baddoura; Isam W Nasr; Barbara Wrobel; Qi Li; Nancy H Ruddle; Fadi G Lakkis
Journal:  Am J Transplant       Date:  2005-03       Impact factor: 8.086

3.  IL-23 secreted by myeloid cells drives castration-resistant prostate cancer.

Authors:  Arianna Calcinotto; Clarissa Spataro; Elena Zagato; Diletta Di Mitri; Veronica Gil; Mateus Crespo; Gaston De Bernardis; Marco Losa; Michela Mirenda; Emiliano Pasquini; Andrea Rinaldi; Semini Sumanasuriya; Maryou B Lambros; Antje Neeb; Roberta Lucianò; Carlo A Bravi; Daniel Nava-Rodrigues; David Dolling; Tommaso Prayer-Galetti; Ana Ferreira; Alberto Briganti; Antonio Esposito; Simon Barry; Wei Yuan; Adam Sharp; Johann de Bono; Andrea Alimonti
Journal:  Nature       Date:  2018-06-27       Impact factor: 49.962

4.  Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures.

Authors:  Marie-Caroline Dieu-Nosjean; Martine Antoine; Claire Danel; Didier Heudes; Marie Wislez; Virginie Poulot; Nathalie Rabbe; Ludivine Laurans; Eric Tartour; Luc de Chaisemartin; Serge Lebecque; Wolf-Herman Fridman; Jacques Cadranel
Journal:  J Clin Oncol       Date:  2008-09-20       Impact factor: 44.544

5.  Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21.

Authors:  Jacqueline D Shields; Iraklis C Kourtis; Alice A Tomei; Joanna M Roberts; Melody A Swartz
Journal:  Science       Date:  2010-03-25       Impact factor: 47.728

6.  Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.

Authors:  Celestia S Higano; Paul F Schellhammer; Eric J Small; Patrick A Burch; John Nemunaitis; Lianng Yuh; Nicole Provost; Mark W Frohlich
Journal:  Cancer       Date:  2009-08-15       Impact factor: 6.860

7.  Cancer-associated fibroblasts and M2-polarized macrophages synergize during prostate carcinoma progression.

Authors:  G Comito; E Giannoni; C P Segura; P Barcellos-de-Souza; M R Raspollini; G Baroni; M Lanciotti; S Serni; P Chiarugi
Journal:  Oncogene       Date:  2013-06-03       Impact factor: 9.867

8.  Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma.

Authors:  S Vesalainen; P Lipponen; M Talja; K Syrjänen
Journal:  Eur J Cancer       Date:  1994       Impact factor: 9.162

Review 9.  A Perspective of Immunotherapy for Prostate Cancer.

Authors:  Ida Silvestri; Susanna Cattarino; Sabrina Giantulli; Cristina Nazzari; Giulia Collalti; Alessandro Sciarra
Journal:  Cancers (Basel)       Date:  2016-07-07       Impact factor: 6.639

10.  Dendritic cells are crucial for maintenance of tertiary lymphoid structures in the lung of influenza virus-infected mice.

Authors:  Corine H GeurtsvanKessel; Monique A M Willart; Ingrid M Bergen; Leonie S van Rijt; Femke Muskens; Dirk Elewaut; Albert D M E Osterhaus; Rudi Hendriks; Guus F Rimmelzwaan; Bart N Lambrecht
Journal:  J Exp Med       Date:  2009-09-28       Impact factor: 14.307

View more
  11 in total

1.  Zonal regulation of collagen-type proteins and posttranslational modifications in prostatic benign and cancer tissues by imaging mass spectrometry.

Authors:  Peggi M Angel; Laura Spruill; Melanie Jefferson; Jennifer R Bethard; Lauren E Ball; Chanita Hughes-Halbert; Richard R Drake
Journal:  Prostate       Date:  2020-07-20       Impact factor: 4.104

2.  Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment.

Authors:  Zhi Qi; Zihan Xu; Liuzhen Zhang; Yongkang Zou; Jinping Li; Wenyu Yan; Cheng Li; Ningshu Liu; Hong Wu
Journal:  Nat Commun       Date:  2022-01-10       Impact factor: 17.694

3.  How else can we approach prostate cancer biomarker discovery?

Authors:  Richard R Drake; Peggi M Angel; Jennifer Wu; Russell K Pachynski; Joseph E Ippolito
Journal:  Expert Rev Mol Diagn       Date:  2019-09-10       Impact factor: 5.225

4.  TGFβ1: An Indicator for Tumor Immune Microenvironment of Colon Cancer From a Comprehensive Analysis of TCGA.

Authors:  Jinyan Wang; Jinqiu Wang; Quan Gu; Yan Yang; Yajun Ma; Quan'an Zhang
Journal:  Front Genet       Date:  2021-04-28       Impact factor: 4.599

5.  M2 subtype tumor associated macrophages (M2-TAMs) infiltration predicts poor response rate of immune checkpoint inhibitors treatment for prostate cancer.

Authors:  Zhou JiaWei; Dou ChunXia; Liu CunDong; Liu Yang; Yang JianKun; Duan HaiFeng; Yang Cheng; Huang ZhiPeng; Wang HongYi; Liao DeYing; Liang ZhiJian; Xie Xiao; Zhou QiZhao; Xue KangYi; Guo WenBing; Xia Ming; Zhou JunHao; Bao JiMing; Zhao ShanChao; Chen MingKun
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

6.  Prognostic Significance of Gene Signature of Tertiary Lymphoid Structures in Patients With Lung Adenocarcinoma.

Authors:  Hong Feng; Fujun Yang; Lihong Qiao; Kai Zhou; Junfei Wang; Jiao Zhang; Tian Tian; Ying Du; Hong Shangguan
Journal:  Front Oncol       Date:  2021-07-26       Impact factor: 6.244

7.  Methylation Pattern Mediated by m6A Regulator and Tumor Microenvironment Invasion in Lung Adenocarcinoma.

Authors:  Feng Jiang; Yifang Hu; Xiaoqin Liu; Ming Wang; Chuyan Wu
Journal:  Oxid Med Cell Longev       Date:  2022-01-05       Impact factor: 6.543

8.  Identification of Novel Diagnostic Biomarkers in Prostate Adenocarcinoma Based on the Stromal-Immune Score and Analysis of the WGCNA and ceRNA Network.

Authors:  Tengfei Zhang; Yaxuan Wang; Yiming Dong; Lei Liu; Yikai Han; Huanrong Wang; Qian Wei; Peige Xia; Wang Ma; Lifeng Li
Journal:  Dis Markers       Date:  2022-01-15       Impact factor: 3.434

9.  The Association between Immune Infiltration and Clinical Phenotypes and Prognosis of Prostate Cancer.

Authors:  Lin Hua; Hong Xia; Weiying Zheng
Journal:  Iran J Biotechnol       Date:  2020-10-01       Impact factor: 1.671

10.  Comprehensive Analysis of the Relationship Between Metabolic Reprogramming and Immune Function in Prostate Cancer.

Authors:  Weijie Xie; Huan Guo; Jiawei Zhang; Li Hu; Yuqi Wu; Xiangwei Wang
Journal:  Onco Targets Ther       Date:  2021-05-18       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.